Abstract 86P
Background
Immune-related adverse events (irAEs) are common side effects of immune checkpoint inhibitor (ICI) cancer therapy, affecting around 50% of the ICI treated patients. IrAEs may be severe and lead to hospitalization, permanent organ damage or the need for long-term immunosuppressants. Hospital admission is a generally known factor of poor prognosis, especially in older patients. This study aimed to investigate the clinical risk factors and prognostic significance of irAE-related hospitalization in metastatic real-world cancer patients.
Methods
The study population included all patients (n=202) with metastatic cancers treated with ICI inhibitors at the Cancer Center of Kuopio University Hospital between 2015 and 2023. Data were manually extracted from the local electronic patient registry. IrAEs, their management, hospital stays, subsequent therapies, progression-free survival (PFS) and overall survival (OS) were evaluated.
Results
Of the patients with irAEs, 26% (31/116) needed inpatient treatment. Hospitalization was associated with severe (grade III to IV) toxicities (p<0.001). The mOS of patients hospitalized due to an irAE was 12.9 months, while that of outpatients with irAEs was 26.9 months (p=0.006). The mOS was especially poor if hospital stay exceeded 6 days (7.0 months vs. 19.1 months, p=0.015). Systemic glucocorticoid therapy was administered to 90.3% of hospitalized and 35.3% of non-hospitalized patients (p<0.05). At disease progression after an irAE, palliative care instead of active oncological therapies was more often provided for hospitalized patients (35.4% vs. 17.6%, p=0.041). At the initiation of salvage systemic therapy after an irAE, hospitalized patients tended to be in poorer physical condition than outpatients (WHO performance status >2 in 35.7% vs. 14.6% of patients, p=0.089).
Conclusions
Hospital admission due to an irAE appeared to significantly deteriorate the survival of ICI treated metastatic cancer patients. This may be attributed to decreased physical fitness due to long admissions and high-dose, long-term glucocorticoid treatments of severe irAEs. Early rehabilitation and effective tapering of corticosteroid, if possible, should be provided for patients hospitalized due to an irAE.
Legal entity responsible for the study
Aino Rönkä.
Funding
State Research Funding for university-level health research, Kuopio University Hospital, Wellbeing Service Country of North Savo, Cancer foundation of Finland, Cancer Society of North Savo, The Finnish Medical Foundation sr, Paavo Koistinen Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
195P - Anti-CTLA4 therapy leads to early expansion of peripheral Th17 population and induction of Th1 cytokines
Presenter: Mari Nakazawa
Session: Poster Display session
Resources:
Abstract
196P - Single-cell analysis of stage-I high-grade serous ovarian carcinoma reveals the essential role of regulatory T cells in early tumor establishment
Presenter: Joanna Mikulak
Session: Poster Display session
Resources:
Abstract
197P - Comprehensive immunoprofiling of the intratumoral and peripheral T cell receptor gene repertoire in triple-negative breast cancer patients
Presenter: Antonios Mingos
Session: Poster Display session
Resources:
Abstract
198P - Association of types of treatment modalities with expression of T Lymphocytes (CD4, CD8, Treg) in breast cancer patients and their clinical outcome
Presenter: Arshi Rizwan
Session: Poster Display session
Resources:
Abstract
199P - Cancer neutrophil encyclopedia: A deep dive into antigen-presenting warriors
Presenter: Yingcheng Wu
Session: Poster Display session
Resources:
Abstract
200P - CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant NSCLC
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
201P - Underlying mechanisms of neutrophil-mediated immunosuppression and resistance to treatment in breast cancer: Further evidence that these cells matter
Presenter: Bruna Filipa Correia
Session: Poster Display session
Resources:
Abstract
202P - Mining tumor infiltrating B cells to discover antibody-target pairs and develop novel therapies
Presenter: Matthieu Delince
Session: Poster Display session
Resources:
Abstract
203P - Targeting IL-33 reprograms tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy
Presenter: Xuyao Zhang
Session: Poster Display session
Resources:
Abstract
204P - Deciphering the crosstalk between tumor and circulating immune microenvironment in advanced NSCLC patients undergoing immunotherapy
Presenter: Prisca Tamarozzi
Session: Poster Display session
Resources:
Abstract